The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease
Table 3
White blood cell subsets and platelets at baseline and 45 and 90 days.
Measure
Reference range
Time
RBAC
Placebo
White blood cells (103/μL
4.3–10.3
Baseline
6.7 ± 2.7 (3.6, 13.8)
5.5 ± 1.1 (2.5, 6.4)
45 days
6.5 ± 2.5 (3.8, 12)
5.8 ± 1.5 (4.2, 9)
90 days
6.7 ± 2.8 (3.4, 13.4)
6 ± 1.6 (2.8, 8.4)
Neutrophils (%)
41–73
Baseline
53.1 ± 9.2 (37.7, 65.7)
56.7 ± 6.1 (45, 67.6)
45 days
50.8 ± 10.2 (25.8, 64.5)
56.4 ± 5.9 (45.8, 65.3)
90 days
48.5 ± 10.6 (25.5, 66.9)
56.6 ± 6.1 (47.6, 64.8)
Lymphocytes (%)
19.4–44.9
Baseline
36.8 ± 7.5 (26, 51.2)
32.7 ± 5.7 (22.9, 42.6)
45 days
37.9 ± 9.6 (23.6, 61.8)
32.8 ± 6.5 (20.2, 42)
90 days
38.6 ± 9.6 (22.2, 60.1)
32.4 ± 4.9 (29.4, 39)
Neutrophil/lymphocyte ratio
None
Baseline
1.5 ± 0.6 (0.7, 2.5)
1.8 ± 0.5 (1.1, 2.5)
45 days
1.5 ± 0.6 (0.4, 2.7)
1.8 ± 0.6 (1.1, 3.0)
90 days
1.4 ± 0.7 (0.4, 3.0)
1.8 ± 0.4 (1.2, 2.3)
Monocytes (%)+
5.1–10.9
Baseline
7.3 ± 2.1 (3.5, 11.8)
7.3 ± 4 (3.6, 18.5)
45 days
7.8 ± 1.2 (5.9, 10.1)
8.1 ± 3.3 (5.5, 16.5)
90 days
9.1 ± 1.3 (6.9, 11.3)
8.1 ± 4.4 (4.5, 19.4)
Eosinophils (%
0.9–6.0
Baseline
2.5 ± 1.3 (1.2, 4.9)
2.9 ± 1.4 (1.1, 5.5)
45 days
3 ± 1.2 (2.1, 5.5)
2.2 ± 1.1 (0.5, 4.1)
90 days
3.3 ± 1.5 (1.6, 6)
2.2 ± 1.2 (0.8, 4.4)
Platelets (103/μL
156–373
Baseline
254.8 ± 90.5 (180, 511)
196.9 ± 61.9 (81, 292)
45 days
225.6 ± 46.7 (170, 311)
194.3 ± 65.3 (55, 267)
90 days
229.5 ± 51.8 (176, 351)
210.4 ± 91.6 (65, 398)
Note. Values are mean ± standard deviation (minimum, maximum). Percent change difference from baseline to 90 days; +percent change difference from 45 days to 90 days; percent change difference from baseline to 45 days.
